Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Provided By GlobeNewswire
Last update: Oct 27, 2025
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology
No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits
Read more at globenewswire.com
